These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 13029820)

  • 1. [Progress in therapy of fetal erythroblastosis].
    PFAU
    Zentralbl Gynakol; 1952; 74(37):1470-2. PubMed ID: 13029820
    [No Abstract]   [Full Text] [Related]  

  • 2. [Heptanes in preventive therapy of fetal erythroblastosis].
    BERGDOLT EG; ROTTMANN EG
    Obstet Ginecol Lat Am; 1951; 9(11-12):545-8. PubMed ID: 14919959
    [No Abstract]   [Full Text] [Related]  

  • 3. [Experiences in prevention and therapy of fetal erythroblastosis].
    SCHEFFLER W
    Zentralbl Gynakol; 1956 Jun; 78(24):962-9. PubMed ID: 13353652
    [No Abstract]   [Full Text] [Related]  

  • 4. Attempt to prevent erythroblastosis foetalis by use of cortisone during pregnancy.
    ANDERSON JR; BARR GM; SLESSOR A
    Br Med J; 1952 Sep; 2(4783):542-4. PubMed ID: 14954156
    [No Abstract]   [Full Text] [Related]  

  • 5. [Studies on prevention of hemolytic disease in newborn].
    POPIVANOV R
    C R Acad Bulg Sci; 1952; 5(2-3):41-4. PubMed ID: 13220500
    [No Abstract]   [Full Text] [Related]  

  • 6. [Prevention of hemolytic disease of the newborn with cortisone].
    CORELLI F; SICILIANO G
    Policlinico Prat; 1952 Nov; 59(45):1485-90. PubMed ID: 13026507
    [No Abstract]   [Full Text] [Related]  

  • 7. [The Rh factor in obstetrics].
    ATTENDU CA
    Union Med Can; 1952 Mar; 81(3):344-5. PubMed ID: 14950959
    [No Abstract]   [Full Text] [Related]  

  • 8. Possible prevention of anti-A isosensitization disease by desensitization of the mother with substance A.
    FLYNN JE
    Am J Clin Pathol; 1952 May; 22(5):418-23. PubMed ID: 14923630
    [No Abstract]   [Full Text] [Related]  

  • 9. [Our experience in the prevention of hemolytic disease of the newborn in the Obstetrics Department of the Policlinico Central de Y.P.F].
    DE LA COLINA C; GALLEGOS R; OTEIZA J
    Prensa Med Argent; 1961 Oct; 48():2899-901. PubMed ID: 13884251
    [No Abstract]   [Full Text] [Related]  

  • 10. Induction of labour to prevent recurrent stillbirth due to haemolytic disease.
    WALKER W; MURRAY S; RUSSELL JK
    Lancet; 1957 Feb; 272(6964):348-50. PubMed ID: 13407010
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prophylaxis of fetal erythroblastosis].
    TAUSEK F
    Osterr Z Kinderheilkd Kinderfuersorge; 1955; 11(2-4):365-8. PubMed ID: 13254089
    [No Abstract]   [Full Text] [Related]  

  • 12. [Therapy and prevention of hemolytic disease of the newborn].
    COUTINHO H
    Gaz Med Port; 1952; 5(3):401-14. PubMed ID: 12980260
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prevention and treatment of fetal erythroblastosis].
    HAILE H
    Arch Gynakol; 1950; 178():350-2. PubMed ID: 15419723
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prevention of fetal erythroblastosis in pregnancy].
    JOSEF C
    Cesk Gynekol; 1950; 15(4-5):353-64. PubMed ID: 15434864
    [No Abstract]   [Full Text] [Related]  

  • 15. [Experiments in the prevention of erythroblastosis].
    ten BERGE BS
    Ned Tijdschr Geneeskd; 1950 Nov; 94(47):3417-8. PubMed ID: 14806583
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevention of kernicterus; management of erythroblastosis fetalis according to current knowledge.
    ALLEN FH; DIAMOND LK
    J Am Med Assoc; 1954 Jul; 155(14):1209-13. PubMed ID: 13174377
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of the bioflavonoid compounds in the prevention or reduction in severity of erythroblastosis fetalis.
    JACOBS WM
    Surg Gynecol Obstet; 1956 Aug; 103(2):233-6. PubMed ID: 13352150
    [No Abstract]   [Full Text] [Related]  

  • 18. [Eldon cards for a complete compatibility test].
    KISSMEYER-NIELSEN F
    Ugeskr Laeger; 1961 Feb; 123():233-5. PubMed ID: 13756423
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical study of prevention of erythroblastosis with Rh hapten.
    WOLF AM; SCHLUTZ C; FREUNDLICH M; LEVINSON SO
    J Am Med Assoc; 1950 Sep; 144(2):88-92. PubMed ID: 15436295
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical significance of Rh factors].
    MATTHES M
    Dtsch Med Wochenschr; 1952 Apr; 77(17):564-5. PubMed ID: 14936615
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.